BRD4 protein inhibitor - Pipeline Insight, 2022

DelveInsight's, "BRD4 protein inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in BRD4 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

BRD4 protein inhibitors Understanding

BRD4 protein inhibitors: Overview

Bromodomain-containing protein 4 (BRD4) is an epigenetic reader that recognizes histone proteins and acts as a transcriptional regulator to trigger tumor growth and the inflammatory response. The pan-bromodomain and extra-terminal domain (BET) inhibitor, (+)-JQ1 (1), was reported to inhibit angiogenesis. A number of Brd4 degraders have been reported and showed more efficient anticancer activities than just protein inhibition. The findings on the novel BRD4 inhibitor suggests that, in addition to being a powerful pharmacological tool for further elucidating the roles and functions of BRD4 and its BD domains in angiogenesis, it may also serve as a potential therapeutic strategy for targeting the vasculature in various angiogenesis-dysregulated human diseases. Inactivating Brd4 or downregulating its expression inhibits cancer development, leading to the current interest in Brd4 as a promising anticancer drug target. Numerous Brd4 inhibitors have been studied in recent years and some of them are currently in various phases of clinical trials.

"BRD4 protein inhibitors - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the BRD4 protein inhibitors pipeline landscape is provided which includes the disease overview and BRD4 protein inhibitors treatment guidelines. The assessment part of the report embraces, in depth BRD4 protein inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, BRD4 protein inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

The companies and academics are working to assess challenges and seek opportunities that could influence BRD4 protein inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve BRD4 protein inhibitors.

BRD4 protein inhibitors Emerging Drugs Chapters

This segment of the BRD4 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

BRD4 protein inhibitors Emerging Drugs

• PLX2853: Plexxikon

An orally bioavailable inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor PLX2853 binds to the acetylated lysine recognition motifs in the bromodomain of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dyregulates gene expression. This may lead to the downregulation of the expression of certain growth-promoting genes, which may induce apoptosis and inhibit the proliferation of BRD4-overexpressing tumor cells. It is currently being evaluated in Phase I/II clinical trial to treat Advanced Malignancies.

Further product details are provided in the report……..

BRD4 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different BRD4 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in BRD4 protein inhibitors

There are approx. 5+ key companies which are developing the therapies for BRD4 protein inhibitors. The companies which have their BRD4 protein inhibitors drug candidates in the most advanced stage, i.e. phase I/II include Plexxikon.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

BRD4 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

BRD4 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses BRD4 protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging BRD4 protein inhibitors drugs.

BRD4 protein inhibitors Report Insights

• BRD4 protein inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

BRD4 protein inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing BRD4 protein inhibitors drugs?
• How many BRD4 protein inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of BRD4 protein inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the BRD4 protein inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for BRD4 protein inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?